How variability in clinical phenotypes should guide research into disease mechanisms in asthma

Annals of the American Thoracic Society

Volumn 10, Issue SUPPL, 2013, Pages

  Chung, Kian Fan ^a   Adcock, Ian M ^b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ANTIGEN EXPRESSION; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL RESEARCH; CLUSTER ANALYSIS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; EOSINOPHIL COUNT; EOSINOPHILIA; HUMAN; NEUTROPHILIA; OBESITY; PERSONALIZED MEDICINE; PHENOTYPE; PROTEOMICS; REVIEW; SYSTEMS BIOLOGY; TH2 CELL; TRANSCRIPTOMICS;

ADRENAL CORTEX HORMONES; ASTHMA; CLUSTER ANALYSIS; EOSINOPHILS; HUMANS; HYPERSENSITIVITY, IMMEDIATE; NEUTROPHILS; OBESITY; PHENOTYPE; SPUTUM; SYSTEMS BIOLOGY; TH2 CELLS; TREATMENT OUTCOME;

EID: 84892509279     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201304-087AW     Document Type: Review

References (83)

1. Rackemann FM. A working classification of asthma. Am J Med 1947;3: 601-606.
2. Carey RA, Harvey AM, Howard JE, Winkenwerder WL. The effect of adrenocorticotropic hormone (ACTH) and cortisone on the course of chronic bronchial asthma. Bull Johns Hopkins Hosp 1950;87:387-414.
3. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, Gibson P, Ohta K, O'Byrne P, Pedersen SE, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31:143-178.
4. Schwartz HJ, Lowell FC, Melby JC. Steroid resistance in bronchial asthma. Ann Intern Med 1968;69:493-499.
5. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, et al.; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59-99.
6. Chung KF, Godard P, Adelroth E, Ayres J, Barnes N, Barnes P, Bel E, Burney P, Chanez P, Connett G, et al.; European Respiratory Society. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. Eur Respir J 1999;13:1198-1208.
7. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000;162: 2341-2351.
8. A plea to abandon asthma as a disease concept. Lancet 2006;368:705.
9. Chung KF, Bel EH, Wenzel SE. Severe asthma: the way forward. In: Chung KF, Bel EH, Wenzel SE, editors. Difficult-to-treat severe asthma. Sheffield, UK: European Respiratory Society; 2011. pp. 297-308.
10. Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008;372:1073-1087.
11. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372:1107-1119.
12. Lötvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, Lemanske RF Jr, Wardlaw AJ, Wenzel SE, Greenberger PA. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011;127: 355-360.
13. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, Macnee W, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010;182:598-604.
14. Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, Calhoun WJ, Castro M, Chung KF, Clark MP, et al.; National Heart, Lung, Blood Institute's Severe Asthma Research Program. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007;119:405-413.
15. Fitzpatrick AM, Teague WG, Meyers DA, Peters SP, Li X, Li H, Wenzel SE, Aujla S, Castro M, Bacharier LB, et al.; National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol 2011;127:382-389, e1-e13.
16. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, Wardlaw AJ, Green RH. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008;178:218-224.
17. Siroux V, Basagaña X, Boudier A, Pin I, Garcia-Aymerich J, Vesin A, Slama R, Jarvis D, Anto JM, Kauffmann F, et al. Identifying adult asthma phenotypes using a clustering approach. Eur Respir J 2011; 38:310-317.
18. Kim TB, Jang AS, Kwon HS, Park JS, Chang YS, Cho SH, Choi BW, Park JW, Nam DH, Yoon HJ, et al. Identification of asthma clusters in two independent Korean adult asthma cohorts. Eur Respir J 2013; 41:1308-1314.
19. Kaneko Y, Masuko H, Sakamoto T, Iijima H, Naito T, Yatagai Y, Yamada H, Konno S, Nishimura M, Noguchi E, et al. Asthma phenotypes in Japanese adults - their associations with the CCL5 and ADRB2 genotypes. Allergol Int 2013;62:113-121.
20. Patrawalla P, Kazeros A, Rogers L, Shao Y, Liu M, Fernandez-Beros ME, Shang S, Reibman J. Application of the asthma phenotype algorithm from the Severe Asthma Research Program to an urban population. PLoS ONE 2012;7:e44540.
21. Sutherland ER, Goleva E, King TS, Lehman E, Stevens AD, Jackson LP, Stream AR, Fahy JV, Leung DY; Asthma Clinical Research Network. Cluster analysis of obesity and asthma phenotypes. PLoS ONE 2012;7:e36631.
22. Gibeon D, Batuwita K, Osmond M, Heaney LG, Brightling CE, Niven RM, Mansur AH, Chaudhuri R, Bucknall CE, Rowe A, et al. Obesity-associated severe asthma represents a distinct clinical phenotype: analysis of the British Thoracic Society Difficult Asthma Registry Patient cohort according to BMI. Chest 2013;143:406-414.
23. Jang AS, Kwon HS, Cho YS, Bae YJ, Kim TB, Park JS, Park SW, Uh ST, Choi JS, Kim YH, et al. Identification of subtypes of refractory asthma in Korean patients by cluster analysis. Lung 2013;191: 87-93.
24. Just J, Gouvis-Echraghi R, Rouve S, Wanin S, Moreau D, Annesi-Maesano I. Two novel, severe asthma phenotypes identified during childhood using a clustering approach. Eur Respir J 2012;40:55-60.
25. Holgate ST. Innate and adaptive immune responses in asthma. Nat Med 2012;18:673-683.
26. Levine SJ, Wenzel SE. Narrative review: the role of Th2 immune pathway modulation in the treatment of severe asthma and its phenotypes. Ann Intern Med 2010;152:232-237.
27. Ziegler SF. Thymic stromal lymphopoietin and allergic disease. J Allergy Clin Immunol 2012;130:845-852.
28. Silverpil E, Lindén A. IL-17 in human asthma. Expert Rev Respir Med 2012;6:173-186.
29. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360: 1715-1721.
30. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-993.
31. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-984.
32. McGrath KW, Icitovic N, Boushey HA, Lazarus SC, Sutherland ER, Chinchilli VM, Fahy JV; Asthma Clinical Research Network of the National Heart, Lung, and Blood Institute. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 2012;185:612-619.
33. Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, Chu HW. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160:1001-1008.
34. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999;160:1532-1539.
35. Lemière C, Ernst P, Olivenstein R, Yamauchi Y, Govindaraju K, Ludwig MS, Martin JG, Hamid Q. Airway inflammation assessed by invasive and noninvasive means in severe asthma: eosinophilic and noneosinophilic phenotypes. J Allergy Clin Immunol 2006;118: 1033-1039.
36. Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, Shikotra A, Carter R, Audusseau S, Hamid Q, et al.; Bronchoscopic Exploratory Research Study of Biomarkers in Corticosteroidrefractory Asthma (BOBCAT) Study Group. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012;130:647-654, e10.
37. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365: 1088-1098.
38. Baines KJ, Simpson JL, Wood LG, Scott RJ, Gibson PG. Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples. J Allergy Clin Immunol 2011; 127:153-160, 160.e1-9.
39. Hastie AT, Moore WC, Meyers DA, Vestal PL, Li H, Peters SP, Bleecker ER; National Heart, Lung, and Blood Institute Severe Asthma Research Program. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol 2010;125: 1028-1036, e13.
40. Wood LG, Simpson JL, Hansbro PM, Gibson PG. Potentially pathogenic bacteria cultured from the sputum of stable asthmatics are associated with increased 8-isoprostane and airway neutrophilia. Free Radic Res 2010;44:146-154.
41. Zhang Q, Illing R, Hui CK, Downey K, Carr D, Stearn M, Alshafi K, Menzies-Gow A, Zhong N, Fan Chung K. Bacteria in sputum of stable severe asthma and increased airway wall thickness. Respir Res 2012;13:35.
42. Fitzpatrick AM, Holguin F, Teague WG, Brown LA. Alveolar macrophage phagocytosis is impaired in children with poorly controlled asthma. J Allergy Clin Immunol 2008;121:1372-1378, 1378.e1-3.
43. Huynh ML, Malcolm KC, Kotaru C, Tilstra JA, Westcott JY, Fadok VA, Wenzel SE. Defective apoptotic cell phagocytosis attenuates PGE2 and 15-hydroxyeicosatetraenoic acid in severe asthma alveolar macrophages. Am J Respir Crit Care Med 2005;172:972-979.
44. Al-Ramli W, Préfontaine D, Chouiali F, Martin JG, Olivenstein R, Lemière C, Hamid QT. T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol 2009;123: 1185-1187.
45. Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, Ellwanger A, Sidhu SS, Dao-Pick TP, Pantoja C, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA 2007;104:15858-15863.
46. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180:388-395.
47. Sorkness RL, Bleecker ER, Busse WW, Calhoun WJ, Castro M, Chung KF, Curran-Everett D, Erzurum SC, Gaston BM, Israel E, et al.; National Heart, Lung, and Blood Institute Severe Asthma Research Program. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol 2008;104:394-403.
48. Busacker A, Newell JD Jr, Keefe T, Hoffman EA, Granroth JC, Castro M, Fain S, Wenzel S. A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis. Chest 2009;135:48-56.
49. Carr D, Hibon S, Chung KF. Peripheral airways obstruction on high resolution computed tomography in chronic severe asthma. Respir Med 1998;92:448-453.
50. Bumbacea D, Campbell D, Nguyen L, Carr D, Barnes PJ, Robinson D, Chung KF. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J 2004;24:122-128.
51. ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001;164:744-748.
52. Aysola RS, Hoffman EA, Gierada D, Wenzel S, Cook-Granroth J, Tarsi J, Zheng J, Schechtman KB, Ramkumar TP, Cochran R, et al. Airway remodeling measured by multidetector CT is increased in severe asthma and correlates with pathology. Chest 2008;134:1183-1191.
53. Kaminska M, Foley S, Maghni K, Storness-Bliss C, Coxson H, Ghezzo H, Lemière C, Olivenstein R, Ernst P, Hamid Q, et al. Airway remodeling in subjects with severe asthma with or without chronic persistent airflow obstruction. J Allergy Clin Immunol 2009;124:45-51.e1-4.
54. Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2006;117:522-543.
55. Bhavsar P, Khorasani N, Hew M, Johnson M, Chung KF. Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma. Eur Respir J 2010;35:750-756.
56. Chang PJ, Bhavsar PK, Michaeloudes C, Khorasani N, Chung KF. Corticosteroid insensitivity of chemokine expression in airway smooth muscle of patients with severe asthma. J Allergy Clin Immunol 2012;130:877-885.e5.
57. Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, Adcock IM. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J 2001;15:1110-1112.
58. Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM. p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002;109:649-657.
59. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003;168:1308-1311.
60. Sutherland ER, Goleva E, Strand M, Beuther DA, Leung DY. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med 2008;178:682-687.
61. Holehouse A, Yang X, Adcock IM, Guo Y. Developing a novel integrated model of p38 MAPK and glucocorticoid signalling pathways. In: Bioinformatics and Computational Biology (CIBCB). Proc. IEEE 2012. pp. 69-76.
62. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, Davies J, Ervine A, Poulter L, Pachter L, et al. Disordered microbial communities in asthmatic airways. PLoS ONE 2010;5:e8578.
63. Huang YJ, Nelson CE, Brodie EL, Desantis TZ, Baek MS, Liu J, Woyke T, Allgaier M, Bristow J, Wiener-Kronish JP, et al.; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. J Allergy Clin Immunol 2011; 127:372-381, e1-e3.
64. Kapitein B, Hoekstra MO, Nijhuis EH, Hijnen DJ, Arets HG, Kimpen JL, Knol EF. Gene expression in CD41 T-cells reflects heterogeneity in infant wheezing phenotypes. Eur Respir J 2008;32:1203-1212.
65. Tsitsiou E, Williams AE, Moschos SA, Patel K, Rossios C, Jiang X, Adams OD, Macedo P, Booton R, Gibeon D, et al. Transcriptome analysis shows activation of circulating CD81 T cells in patients with severe asthma. J Allergy Clin Immunol 2012;129:95-103.
66. Jardim MJ, Dailey L, Silbajoris R, Diaz-Sanchez D. Distinct microRNA expression in human airway cells of asthmatic donors identifies a novel asthma-associated gene. Am J Respir Cell Mol Biol 2012;47:536-542.
67. Solberg OD, Ostrin EJ, Love MI, Peng JC, Bhakta NR, Hou L, Nguyen C, Solon M, Nguyen C, Barczak AJ, et al. Airway epithelial miRNA expression is altered in asthma. Am J Respir Crit Care Med 2012; 186:965-974.
68. Levänen B, Bhakta NR, Torregrosa Paredes P, Barbeau R, Hiltbrunner S, Pollack JL, Sköld CM, Svartengren M, Grunewald J, Gabrielsson S, et al. Altered microRNA profiles in bronchoalveolar lavage fluid exosomes in asthmatic patients. J Allergy Clin Immunol 2013;131: 894-903.
69. Fu JJ, Baines KJ, Wood LG, Gibson PG. Systemic inflammation is associated with differential gene expression and airway neutrophilia in asthma. OMICS 2013;17:187-199.
70. Nicholas B, Skipp P, Mould R, Rennard S, Davies DE, O'Connor CD, Djukanović R. Shotgun proteomic analysis of human-induced sputum. Proteomics 2006;6:4390-4401.
71. Gharib SA, Nguyen EV, Lai Y, Plampin JD, Goodlett DR, Hallstrand TS. Induced sputum proteome in healthy subjects and asthmatic patients. J Allergy Clin Immunol 2011;128:1176-1184.e6.
72. O'Neil SE, Sitkauskiene B, Babusyte A, Krisiukeniene A, Stravinskaite-Bieksiene K, Sakalauskas R, Sihlbom C, Ekerljung L, Carlsohn E, Lötvall J. Network analysis of quantitative proteomics on asthmatic bronchi: effects of inhaled glucocorticoid treatment. Respir Res 2011;12:124.
73. Wang H, Chavali S, Mobini R, Muraro A, Barbon F, Boldrin D, Aberg N, Benson M. A pathway-based approach to find novel markers of local glucocorticoid treatment in intermittent allergic rhinitis. Allergy 2011;66:132-140.
74. Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest 2010;137:1410-1416.
75. Chen R, Snyder M. Promise of personalized omics to precision medicine. Wiley Interdiscip Rev Syst Biol Med 2013;5:73-82.
76. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
77. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013;152:714-726.
78. Barrenäs F, Chavali S, Alves AC, Coin L, Jarvelin MR, Jörnsten R, Langston MA, Ramasamy A, Rogers G, Wang H, et al. Highly interconnected genes in disease-specific networks are enriched for disease-associated polymorphisms. Genome Biol 2012;13:R46.
79. Ghosh S, Matsuoka Y, Asai Y, Hsin KY, Kitano H. Software for systems biology: from tools to integrated platforms. Nat Rev Genet 2011;12:821-832.
80. Vera J, Wolkenhauer O. A system biology approach to understand functional activity of cell communication systems. Methods Cell Biol 2008;90:399-415.
81. Lauzon AM, Bates JH, Donovan G, Tawhai M, Sneyd J, Sanderson MJ. A multi-scale approach to airway hyperresponsiveness: from molecule to organ. Front Physiol 2012;3:191.
82. Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, Wagener AH, Wagers SS, Sterk PJ, Compton CH; Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-BIOPRED) Consortium, Consensus Generation. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011;66:910-917.
83. Just J, Gouvis-Echraghi R, Couderc R, Guillemot-Lambert N, Saint-Pierre P. Novel severe wheezy young children phenotypes: boys atopic multiple-trigger and girls nonatopic uncontrolled wheeze. J Allergy Clin Immunol 2012;130:103-110, e8.